Tonix Pharmaceuticals Holding Corp
tonixpharma.comTonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company focused on developing and commercializing central nervous system and other therapeutic drug candidates. Revenue, to the extent generated, is expected to come from commercial sales of approved products, with TONMYA (its fibromyalgia treatment) representing the first approved product entering commercial launch as of the fiscal year ended December 31, 2025. The company has no meaningful product revenue history disclosed in the filing excerpts and funds operations through public and private capital raises. Tonix holds exclusive license agreements with various institutions covering patents and technical information, with milestone obligations ranging from $25,000 to $5.0 million per agreement (as of December 31, 2025). Outstanding research and development contract commitments totaled approximately $52.3 million as of December 31, 2025. The company reported stock-based compensation of $6.0 million for the year ended December 31, 2025, split between general and administrative ($4.1 million) and research and development ($1.9 million). Tonix relies on third-party contract manufacturers and contract research organizations for drug production and clinical development.
Products & Services
TONMYA: FDA-approved treatment for fibromyalgia, entering commercial launch as of the fiscal year ended December 31, 2025. TNX-801: a medical countermeasure candidate for which the U.S. government is described as the primary market. Additional undisclosed pipeline candidates in research and development.
Revenue Model
Product sales from commercially launched drugs, with TONMYA for fibromyalgia as the first commercial product. No material product revenue is evidenced in the filing excerpts. The company has historically funded operations through equity and debt capital raises.
Customers & Markets
Fibromyalgia patients and prescribing physicians for TONMYA. U.S. government as the primary buyer for medical countermeasure candidate TNX-801. Third-party insurance companies and government agencies are identified as material reimbursement decision-makers.
Geographic Exposure
Primarily U.S.-focused based on disclosed regulatory and commercial activities. European regulatory pathways (EMA, EU Marketing Authorization) are referenced as potential future markets, but no approved products or revenue in foreign markets are evidenced in the filing excerpts.
Financial Snapshot
Loading...
